Goldman Sachs Acquires Control of Italian Medtech Firm Numantec

Goldman Sachs Alternatives has announced its acquisition of a controlling stake in Numantec, a prominent Italian medical equipment manufacturer. The deal, finalized with White Bridge Investment, represents a significant move for Goldman Sachs in the healthcare industry amid ongoing economic uncertainties.

Numantec's Strategic Position in Medtech

Based near Mantua, Italy, Numantec is known for supplying a diverse array of healthcare products and drug-delivery devices. The company employs approximately 600 people and operates seven manufacturing facilities across Europe and the United States. Numantec's strategic expansion began with White Bridge Investment's initial venture into Delta Med, a manufacturer specializing in vascular access devices, in 2021. Since then, Numantec has grown through a series of acquisitions, including the recent purchase of Health Line International, which facilitated its entry into the U.S. market.

Details of the Acquisition

While the financial specifics of the transaction remain undisclosed, sources familiar with the matter estimate the sale values Numantec at around €700 million. The acquisition is anticipated to close in the fourth quarter of 2026. Under the new ownership, Numantec is expected to continue its expansion within Europe and further solidify its presence in the U.S. market.

Advisors and Market Implications

JPMorgan served as the financial advisor to White Bridge for this transaction, while Goldman Sachs International advised Goldman Sachs Alternatives. This acquisition is seen as a strategic move by Goldman Sachs to strengthen its portfolio in the medical technology sector, capitalizing on Numantec's established market position and potential for growth.

The acquisition underscores the increasing interest in medtech companies, which have shown resilience and potential for steady revenue streams even amid global economic challenges. By integrating Numantec's capabilities, Goldman Sachs aims to enhance its influence and offerings in the healthcare market.